Medinol tries to end supply deal with Boston
This article was originally published in Clinica
Boston Scientific has rejected development partner Medinol's claims that the Israeli company is ending their joint 10-year stent supply agreement. Medinol is claiming alleged breaches of the agreement by Boston, which the US company denies. Under the deal, Boston has exclusive worldwide rights to sell the stents.